In latest deal, Melinta executes $270M pact to buy out Medicines Co’s infectious disease group
As promised, The Medicines Company has found a buyer for its infectious disease unit. Wheeling and dealing its way through the year, Melinta Therapeutics has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.